JPWO2020259528A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020259528A5 JPWO2020259528A5 JP2021576479A JP2021576479A JPWO2020259528A5 JP WO2020259528 A5 JPWO2020259528 A5 JP WO2020259528A5 JP 2021576479 A JP2021576479 A JP 2021576479A JP 2021576479 A JP2021576479 A JP 2021576479A JP WO2020259528 A5 JPWO2020259528 A5 JP WO2020259528A5
- Authority
- JP
- Japan
- Prior art keywords
- body weight
- days
- compound
- formula
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000037396 body weight Effects 0.000 claims 70
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000001204 N-oxides Chemical class 0.000 claims 8
- 150000002148 esters Chemical class 0.000 claims 8
- 239000002207 metabolite Substances 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- -1 cyclic hydrocarbyl Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019092675 | 2019-06-25 | ||
| CNPCT/CN2019/092675 | 2019-06-25 | ||
| PCT/CN2020/097881 WO2020259528A1 (zh) | 2019-06-25 | 2020-06-24 | 治疗特发性肺纤维化的方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022539329A JP2022539329A (ja) | 2022-09-08 |
| JP2022539329A5 JP2022539329A5 (https=) | 2023-06-29 |
| JPWO2020259528A5 true JPWO2020259528A5 (https=) | 2023-06-29 |
| JP7615061B2 JP7615061B2 (ja) | 2025-01-16 |
Family
ID=74061495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576479A Active JP7615061B2 (ja) | 2019-06-25 | 2020-06-24 | 特発性肺線維症を治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12582653B2 (https=) |
| EP (1) | EP3992183A4 (https=) |
| JP (1) | JP7615061B2 (https=) |
| KR (1) | KR20220029681A (https=) |
| CN (2) | CN114026072A (https=) |
| AU (1) | AU2020305979B2 (https=) |
| BR (1) | BR112021026214A2 (https=) |
| CA (1) | CA3144113A1 (https=) |
| IL (1) | IL289192A (https=) |
| TW (1) | TWI804743B (https=) |
| WO (1) | WO2020259528A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023539276A (ja) * | 2020-08-31 | 2023-09-13 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｒｈｏ関連タンパク質キナーゼ阻害剤の塩、その固体形態、その調製方法およびその使用 |
| CA3209240A1 (en) * | 2021-02-22 | 2022-08-25 | Samuel D. Waksal | Rock2 inhibitor for the treatment of viral infection |
| NO346587B1 (en) * | 2021-06-02 | 2022-10-17 | Axichem Ab | Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis |
| TW202327608A (zh) * | 2021-09-17 | 2023-07-16 | 北京泰德製藥股份有限公司 | 治療病毒感染的方法 |
| IL311447A (en) * | 2021-09-18 | 2024-05-01 | Beijing Tide Pharmaceutical Co Ltd | A solid form of a Rho-linked protein kinase inhibitor or a solvate thereof, a method of preparation and use thereof |
| KR20240095429A (ko) * | 2021-11-16 | 2024-06-25 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Rock2 억제제의 나노결정 제제 및 이의 제조방법 |
| WO2023134688A1 (zh) * | 2022-01-13 | 2023-07-20 | 武汉朗来科技发展有限公司 | 一种rock抑制剂的盐及盐的晶型、组合物和药物用途 |
| EP4591863A1 (en) * | 2022-10-13 | 2025-07-30 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating pneumoconiosis |
| WO2025017499A1 (en) | 2023-07-17 | 2025-01-23 | Graviton Bioscience Bv | Formulations and uses of rock2 inhibitors for als |
| IL325831A (en) | 2023-07-17 | 2026-03-01 | Graviton Bioscience Bv | ROCK2 inhibitor formulations for central nervous system disorders |
| WO2025069008A1 (en) | 2023-09-28 | 2025-04-03 | Graviton Bioscience Bv | Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors |
| WO2025069009A1 (en) | 2023-09-29 | 2025-04-03 | Graviton Bioscience Bv | Rock2 inhibitors in the treatment of obesity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016138335A1 (en) * | 2015-02-27 | 2016-09-01 | Lycera Corporation | Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease |
| AR110401A1 (es) | 2016-12-21 | 2019-03-27 | Chiesi Farm Spa | Derivados dihidropirimidina bicíclica-carboxamida como inhibidores de rho-quinasa |
| CN110582489B (zh) * | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| WO2019000682A1 (zh) * | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
-
2020
- 2020-06-24 CA CA3144113A patent/CA3144113A1/en active Pending
- 2020-06-24 TW TW109121568A patent/TWI804743B/zh active
- 2020-06-24 BR BR112021026214A patent/BR112021026214A2/pt unknown
- 2020-06-24 CN CN202080045478.XA patent/CN114026072A/zh active Pending
- 2020-06-24 JP JP2021576479A patent/JP7615061B2/ja active Active
- 2020-06-24 US US17/621,719 patent/US12582653B2/en active Active
- 2020-06-24 WO PCT/CN2020/097881 patent/WO2020259528A1/zh not_active Ceased
- 2020-06-24 CN CN202510159677.8A patent/CN119868365A/zh active Pending
- 2020-06-24 EP EP20833444.1A patent/EP3992183A4/en active Pending
- 2020-06-24 AU AU2020305979A patent/AU2020305979B2/en active Active
- 2020-06-24 KR KR1020227002368A patent/KR20220029681A/ko active Pending
-
2021
- 2021-12-21 IL IL289192A patent/IL289192A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020259528A5 (https=) | ||
| JP2020125355A (ja) | 併用療法 | |
| CN115190815A (zh) | 芳基环己基胺衍生物及其在精神障碍的治疗中的用途 | |
| JP6745726B2 (ja) | 中枢神経系障害の処置における２，４−チアゾリジンジオン誘導体 | |
| KR20150013527A (ko) | 항염증 활성과 접합된 증진된 항인플루엔자제 | |
| EP2959903B1 (en) | Medicine for treating eye disease | |
| JP2021147322A (ja) | ステロイド系化合物及びその医薬用途 | |
| JPH0144170B2 (https=) | ||
| JP2017522304A5 (https=) | ||
| KR20140048239A (ko) | 아미노 프로판디올 유도체, 제조방법 및 약제학적 조성물 및 사용 | |
| JP2014523887A5 (https=) | ||
| US5696126A (en) | Prodrug esters of phenolic 2-piperidino-1-alkanols | |
| US8147880B2 (en) | Polyacetylenic compounds for stimulating insulin gene exression, production and secretion | |
| US20210363110A1 (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
| JPWO2020177587A5 (https=) | ||
| WO2017100703A1 (en) | Ems analogues of lyn/src-tyrosine kinase inhibitors | |
| JPWO2022017412A5 (https=) | ||
| KR20010013387A (ko) | 통증을 치료하기 위한 드라플라진-유사체의 용도 | |
| US20040092595A1 (en) | Analgesic agent | |
| JPWO2020221274A5 (https=) | ||
| JP2007500205A5 (https=) | ||
| JP2006347942A (ja) | βアミロイド生成抑制剤 | |
| JP2000229977A (ja) | トリデカノリド誘導体及び抗癌剤 | |
| JPH11217361A (ja) | ナフトキノン化合物及び該化合物からなる医薬 | |
| JP2020507608A5 (https=) |